{"schema_version":"secwatch.filing_event.v1","accession":"0001404644-26-000046","form_type":"8-K","ticker":"NGNE","cik":"0001404644","company_name":"Neurogene Inc.","filed_at":"2026-06-29T12:00:50+00:00","discovered_at":"2026-06-29T12:05:00.267735+00:00","generated_at":"2026-06-29T12:05:22.269963+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Neurogene reports positive Phase 1/2 data for NGN-401 in Rett syndrome; 47 milestones gained across 10 patients","bullets":["47 developmental milestones gained across 10 participants (avg 4.7); 100% improved CGI-I and gained ≥1 milestone.","Durable effect through 30 months with no plateau or milestone loss; median time to first improvement 2 months.","NGN-401 generally well-tolerated; no new treatment-related SAEs since Oct 2025; all AEs mild or moderate.","Dosing complete in Embolden registrational trial; no treatment-related SAEs or DLTs; topline data expected 2H 2027.","Improvements across RSGMS and RSHFS scales (p<0.001); 7/10 gained ≥2 milestones across ≥2 Rett domains."],"urls":{"canonical":"https://secwatch.observer/filing/0001404644-26-000046","json":"https://secwatch.observer/filing/0001404644-26-000046.json","markdown":"https://secwatch.observer/filing/0001404644-26-000046.md","text":"https://secwatch.observer/filing/0001404644-26-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404644/000140464426000046/0001404644-26-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404644/000140464426000046/ngne-20260629.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T12:05:22.269963+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}